Insider Sell: CBO & EVP Thomas Kassberg Sells 39,878 Shares of Ultragenyx Pharmaceutical Inc
On October 23, 2023, Thomas Kassberg, the Chief Business Officer and Executive Vice President of Ultragenyx Pharmaceutical Inc (NASDAQ:RARE), sold 39,878 shares of the company. This move is part of a series of transactions made by the insider over the past year, during which Kassberg has sold a total of 41,846 shares and made no purchases.
Ultragenyx Pharmaceutical Inc is a biopharmaceutical company committed to bringing novel products to patients for the treatment of serious rare and ultra-rare genetic diseases. The company's diverse pipeline includes biologics, small molecule substrates, and gene therapy candidates targeting a range of severe genetic diseases. Ultragenyx has built a broad and diverse pipeline of product candidates with the potential to address diseases for which the unmet medical need is high and for which there are no approved therapies.
The insider transaction history for Ultragenyx Pharmaceutical Inc shows a clear trend of insider selling over the past year. There have been 19 insider sells and no insider buys. This could be a signal to investors to be cautious, as it might indicate that those with the most insight into the company's operations see limited upside or potential downside.
On the day of the insider's recent sell, shares of Ultragenyx Pharmaceutical Inc were trading for $32.78 apiece, giving the stock a market cap of $2.62 billion.
With a price of $32.78 and a GuruFocus Value of $80.83, Ultragenyx Pharmaceutical Inc has a price-to-GF-Value ratio of 0.41. This suggests that the stock is a possible value trap, and investors should think twice before investing. The GF Value is an intrinsic value estimate developed by GuruFocus, calculated based on historical multiples, a GuruFocus adjustment factor based on the companys past returns and growth, and future estimates of business performance from Morningstar analysts.
In conclusion, the recent insider sell by Thomas Kassberg, coupled with the overall trend of insider selling at Ultragenyx Pharmaceutical Inc, may be a cautionary signal for investors. The company's current valuation also suggests that the stock may be overpriced relative to its intrinsic value. As always, investors should conduct their own due diligence and consider multiple factors before making investment decisions.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
This article first appeared on GuruFocus.
